Boan Biotech: BA2201 Approved for Clinical Trial in China, Intended for the Treatment of Inflammatory Bowel Disease

On November 6, Boan Biotech announced that its independently developed Class 1 innovative drug BA2201 has received approval from the Center for Drug Evaluation of China's National Medical Products Administration to conduct clinical trials. The investigational drug is a long-acting bispecific antibody targeting TL1A and IL-23, intended for the treatment of autoimmune diseases such as inflammatory bowel disease.